207 related articles for article (PubMed ID: 22235273)
1. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.
Durfort T; Tkach M; Meschaninova MI; Rivas MA; Elizalde PV; Venyaminova AG; Schillaci R; François JC
PLoS One; 2012; 7(1):e29213. PubMed ID: 22235273
[TBL] [Abstract][Full Text] [Related]
2. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
Schillaci R; Salatino M; Cassataro J; Proietti CJ; Giambartolomei GH; Rivas MA; Carnevale RP; Charreau EH; Elizalde PV
J Immunol; 2006 Mar; 176(6):3426-37. PubMed ID: 16517711
[TBL] [Abstract][Full Text] [Related]
3. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells.
An Y; Cai Y; Guan Y; Cai L; Yang Y; Feng X; Zheng J
Cancer Biother Radiopharm; 2010 Oct; 25(5):545-52. PubMed ID: 20950153
[TBL] [Abstract][Full Text] [Related]
6. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis.
Kaulfuss S; Burfeind P; Gaedcke J; Scharf JG
Mol Cancer Ther; 2009 Apr; 8(4):821-33. PubMed ID: 19372555
[TBL] [Abstract][Full Text] [Related]
7. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
Balañá ME; Labriola L; Salatino M; Movsichoff F; Peters G; Charreau EH; Elizalde PV
Oncogene; 2001 Jan; 20(1):34-47. PubMed ID: 11244498
[TBL] [Abstract][Full Text] [Related]
8. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor].
Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931
[No Abstract] [Full Text] [Related]
9. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Chernicky CL; Tan H; Yi L; Loret de Mola JR; Ilan J
Mol Pathol; 2002 Apr; 55(2):102-9. PubMed ID: 11950959
[TBL] [Abstract][Full Text] [Related]
10. [Biological behaviors and chemosensitivity of NSCLC A549 cells after IGF-IR gene silencing by targeting RNAi in vitro].
Kong MJ; Dong AQ; Wu W; Ma ZY; Cheng HF; Qian JF; Fan JQ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 37(4):373-80. PubMed ID: 18705010
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
[TBL] [Abstract][Full Text] [Related]
12. Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis.
Subramani R; Lopez-Valdez R; Arumugam A; Nandy S; Boopalan T; Lakshmanaswamy R
PLoS One; 2014; 9(5):e97016. PubMed ID: 24809702
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro.
Yavari K; Taghikhani M; Maragheh MG; Mesbah-Namin SA; Babaei MH
Arch Med Res; 2009 May; 40(4):235-40. PubMed ID: 19608011
[TBL] [Abstract][Full Text] [Related]
14. Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.
Watson KL; Moorehead RA
BMC Cancer; 2013 Aug; 13():375. PubMed ID: 23919516
[TBL] [Abstract][Full Text] [Related]
15. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
16. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
[TBL] [Abstract][Full Text] [Related]
17. [Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer].
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Charreau EH; Elizalde PV
Medicina (B Aires); 2004; 64(2):129-34. PubMed ID: 15628299
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells.
Zhu Z; Xu T; Wang L; Wang X; Zhong S; Xu C; Shen Z
FEBS Lett; 2014 Aug; 588(17):3180-5. PubMed ID: 24999188
[TBL] [Abstract][Full Text] [Related]
19. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
[TBL] [Abstract][Full Text] [Related]
20. Preneoplastic changes persist after IGF-IR downregulation and tumor regression.
Jones RA; Petrik JJ; Moorehead RA
Oncogene; 2010 Aug; 29(34):4779-86. PubMed ID: 20543862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
